CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

GSK is scheduled to report results for the first quarter on Wednesday. Here is what to know. SALES FORECAST: The British pharmaceutical giant is expected to report sales for the period of 7.42 ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine segment. See why the stock is a Buy.

For new and old investors, taking full advantage of the stock market and investing with confidence are common ... which is more than double the S&P 500's performance over the same time frame. However, ...

GSK GSK 0.99 % increase; green up pointing triangle plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.

We aim to explore its current performance. Present Market Standing of GSK With a volume of 19,701,072, the price of GSK is up 5.97% at $40.29.

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

This article was corrected at 0907 GMT to reflect GSK's core earnings per share fell 10% at constant currencies to 23.2 pence, above analysts' expectations of 20.6 pence.

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment, the company said on Wednesday.

GSK’s blood cancer drug Blenrep won regulatory approval in the U.K., marking the medicine’s return to the market after it was withdrawn several years ago.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.40. The company’s shares opened today ...

Assuming GSK prices its triple therapy combination at a 20 percent discount to sum total of cost of individual therapies (LAMA + LABA + ICS), the market opportunity available to it would be $2.7b.